Maxim Group Reaffirms Hold Rating for bioAffinity Technologies (NASDAQ:BIAF)

bioAffinity Technologies (NASDAQ:BIAF)‘s stock had its “hold” rating reiterated by Maxim Group in a research note issued to investors on Tuesday,Benzinga reports.

bioAffinity Technologies Stock Performance

NASDAQ:BIAF opened at $0.89 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.02 and a quick ratio of 1.01. The firm has a market cap of $13.87 million, a PE ratio of -1.09 and a beta of 3.12. The firm has a 50 day simple moving average of $0.58 and a 200-day simple moving average of $1.06. bioAffinity Technologies has a 1-year low of $0.24 and a 1-year high of $3.16.

bioAffinity Technologies (NASDAQ:BIAF) last released its earnings results on Monday, March 31st. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.07). bioAffinity Technologies had a negative return on equity of 205.09% and a negative net margin of 91.22%. The business had revenue of $2.20 million for the quarter, compared to analysts’ expectations of $2.42 million.

Institutional Inflows and Outflows

An institutional investor recently raised its position in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC grew its position in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 46,304 shares of the company’s stock after acquiring an additional 26,304 shares during the quarter. Sheaff Brock Investment Advisors LLC owned about 0.30% of bioAffinity Technologies worth $42,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 1.64% of the company’s stock.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.